Capivasertib (generic name: Capivasertib) is not yet officially available in the Chinese market. Actual costs are significantly affected by dosage, purchase channels, health insurance policies, and assistance programs.
Key Factors Affecting Price
Region and Market Status
Developed by AstraZeneca, capivasertib has been approved in some countries for the treatment of certain types of breast and prostate cancer, but in China it is still in the clinical trial or approval stage. Patients in regions where it is not yet available need to obtain it through special channels (such as the "pilot" policy in the Hainan Free Trade Zone) or overseas channels, and the price may be significantly higher than in regions where it is already available.
Dosage and Treatment Duration
The standard treatment regimen is usually 400mg twice daily, with each box of 112 tablets covering approximately two weeks of treatment. The treatment cycle is long (usually several months), and the total cost may reach hundreds of thousands of yuan. Some patients may require dosage adjustments based on their condition, further affecting the overall cost.
Health Insurance and Patient Assistance
In countries where it is already available, commercial insurance or government health insurance can cover part of the cost. For example, some insurance plans in the United States can reimburse 50%-80% of costs; European countries reduce out-of-pocket expenses through universal health insurance systems. In addition, pharmaceutical companies may offer Patient Assistance Programs (PAPs), which eligible individuals can apply for fee reductions or exemptions.
Cost Optimization Recommendations
Monitor the progress of drug approvals in China: The National Medical Products Administration (NMPA) has included some anti-cancer drugs in its priority review process; it is recommended to track their market launch status through official channels.
Consult professional institutions: Some cross-border medical institutions can assist in compliant drug procurement; however, it is crucial to ensure the legality of the procurement channels and the quality of the drugs.
Apply for clinical trials: If relevant clinical trials in China are open for recruitment, participation can provide free access to the drugs and professional monitoring.
Important Reminders
Purchasing drugs from overseas carries the risk of counterfeit medications; the source of the drugs must be strictly verified.
Before using any medication, genetic testing is required to confirm the indication (e.g., PIK3CA/AKT1/PTEN gene mutations) to avoid ineffective treatment.
Other costs may arise during treatment (e.g., testing, adjuvant therapy, etc.); a comprehensive assessment of the financial burden is necessary.
For specific pricing or medication guidance, it is recommended to consult with the oncology department of a reputable hospital or through official channels of the pharmaceutical company.
